


FORM PTO-1449
(Rev. 7-13)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No. **6258.200-US**Serial No. **09/996,023**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Lau et al**Filing Date **November 16, 2001**Group **1626 To be assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,880,139	03/09/99	L.L. Chang	514	326	11/17/97
	5,776,954	07/07/98	de Laszlo et al	514	340	10/30/96
	4,359,474	11/16/82	Anderson et al	424	273	11/28/80
	4,374,130	02/15/83	Barcza	424	184	02/15/83
	5,837,719	11/17/98	de Laszlo et al	514	343	08/08/96

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 00/39088	06/07/00	WIPO	—	—		
	WO 94/14426	07/07/94	WIPO	—	—		
	WO 98/04528	05/02/98	WIPO	—	—		
	WO 98/21957	28/05/98	WIPO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C.L. Brand et al., 'Immunoneutralization of endogenous glucagons with Monoclonal glucagons antibody normalizes hyperglycaemia in moderately Streptozotocin-diabetic rats' 'Diabetologia, Vol. 37 pgs.985-993 (1994)
	C.L. Brand et al [535] Diabetes 43, [suppl 1], 172A (1994)
	C.L. Brand et al., Am J. Physiol. 269, E469-E477 (1995)
	C.L. Brand et al [492] Diabetes 44 [suppl 1], 134A (1995)
	C.L. Brand et al., 'Evidence for a Major Role for Glucagon in Regulation of Plasma Glucose in Conscious, Nondiabetic, and Alloxan Induced Diabetic Rabbits', Diabetes Vol. 45, pgs. 1076-1083 (1996)
	L.J. Jelinek et al., 'Expression Cloning and Signaling Properties of the Rat Glucagon Receptor' 'Science Vol. 259, pgs. 1614-1616 (1993)

EXAMINER

DATE CONSIDERED

10/1/02


EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 24 2002
TECH CENTER 1600/2900

FORM PTO-1049
(Rev. 2-3-99)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6258.200-US

Serial No. 09/996,023

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant Lau et al

Filing Date November 16, 2001

Group 1626
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
888	WO 98/22108	28/05/98	WIPO	—	—		
888	WO 98/22109	28/05/98	WIPO	—	—		
888	WO 99/01423	14/01/99	WIPO	—	—		
888	WO 97/16442	09/05/97	WIPO	—	—		
888	WO 98/24780	11/06/98	WIPO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

888	J.L. Collins et al., 'CP-99, 711: A Non-Peptide Glucagon Receptor Antagonist' Bioorganic & Med.Chem. Ltr. Vol.2, No.9, pgs.915-918 (1992)
888	P. Madsen et al., 'Discovery and Structure-Activity Relationship of the First Non-Peptide Competitive Human Glucagon Receptor Antagonists' J. Med.Chem Vol. 41, pages. 5150-5157 (1998)

EXAMINER

DATE CONSIDERED

10/1/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

APR 24 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900
FEB 01 2002

RECEIVED
APR 24 2007
TECH CENTER 1600/2900

Applicant **Lau et al**

(Use several sheets if necessary)

Filing Date November 16, 2001

Group ~~1614~~ 1626

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

RECEIVED

JUN 12 2002

TECH CENTER 1600/2900

[illegible][illegible]

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.